A Study of Tarceva for Use in Patients With Relapsed or Refractory Metastatic Non-Small Cell Lung Cancer
Status:
Terminated
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
Tarceva, an orally available small molecule, has demonstrated potent activity in tumor models
and humans. This randomized, open-label phase 2 study of Tarceva alone and of Tarceva plus
VELCADE is designed primarily to determine the objective tumor response rates to these
treatments in patients with Stage IIIB or Stage IV non-small cell lung cancer (NSCLC) that is
refractory to or has relapsed after front-line chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Millennium Pharmaceuticals, Inc.
Collaborator:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.